A phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 [KU 59436] given orally twice daily in patients with advanced BRCA1 or BRCA2 associated ovarian cancer

Trial Profile

A phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 [KU 59436] given orally twice daily in patients with advanced BRCA1 or BRCA2 associated ovarian cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Olaparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms ICEBERG-2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 27 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top